Compare CYRX & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYRX | RCS |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.7M | 308.9M |
| IPO Year | N/A | N/A |
| Metric | CYRX | RCS |
|---|---|---|
| Price | $9.37 | $6.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $12.83 | N/A |
| AVG Volume (30 Days) | ★ 594.0K | 141.1K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $243,795,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $7.44 | ★ N/A |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $4.51 |
| 52 Week High | $11.44 | $6.31 |
| Indicator | CYRX | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 44.31 |
| Support Level | $9.08 | $6.54 |
| Resistance Level | $10.30 | $7.04 |
| Average True Range (ATR) | 0.46 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 42.94 | 39.33 |
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.